Dunamu's investment subsidiary, Dunamu Partners, announced on August 4 that it has made a follow-up investment in InnoClass, a cancer genomics big data company.
InnoClass is a startup co-founded in 2020 by Professors Yoo Young-seok and Lee Jeong-seok from the Korea Advanced Institute of Science and Technology (KAIST). The company possesses proprietary technology that converts complex genomic data into actionable information for clinical use. Currently, over 100 cancer-specialized medical institutions in Asia are utilizing InnoClass's solutions.
Dunamu Partners began its investment journey in 2022, guided by a philosophy of supporting companies led by Korean scientists from the early stages. The firm has participated in all four funding rounds, accumulating a total investment of 14.5 billion won.
InnoClass CEO Seo Je-hee stated, "Dunamu Partners has been a strategic partner that has contributed to InnoClass's growth beyond just being a financial investor." He added, "Their advice on building a sustainable revenue model based on clinical experience accumulated in the Asian market has been a crucial turning point for the company to establish itself in the market and lay the groundwork for business expansion."
InnoClass raised a total of $31 million (approximately 44.3 billion won) in this funding round. DSC Investment and Intervest participated in the follow-up investment, while IMM Investment, Korea Investment & Securities, Woori Investment & Securities, and Shinhan Investment Corp. joined as new investors. InnoClass plans to use the secured funds to aggressively target the U.S. hospital market.
Lee Kang-jun, CEO of Dunamu Partners, expressed high expectations for InnoClass's growth potential, stating, "The company is evolving into a data platform that not only dramatically improves the diagnosis of major diseases that humanity must overcome, such as cancer and rare diseases, but also leads global new drug development based on accumulated genomic big data."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.